BACKGROUND: After HIV diagnosis and linkage to care, achieving and sustaining viral load (VL) suppression has implications for patient outcomes and secondary HIV prevention. We evaluated factors associated with expeditious VL suppression and cumulative VL burden among patients establishing outpatient HIV care. METHODS: Patients initiating HIV medical care from January 2007 to October 2010 at the University of Alabama at Birmingham and University of Washington were included. Multivariable Cox proportional hazards and linear regression models were used to evaluate factors associated with time to VL suppression (<50 copies/mL) and cumulative VL burden, respectively. Viremia copy-years, a novel area under the longitudinal VL curve measure, was used to estimate 2-year cumulative VL burden from clinic enrollment. RESULTS: Among 676 patients, 63% achieved VL <50 copies per milliliter in a median 308 days. In multivariable analysis, patients with more time-updated "no show" visits experienced delayed VL suppression (hazard ratio = 0.84 per "no show" visit, 95% confidence interval = 0.76 to 0.92). In multivariable linear regression, visit nonadherence was independently associated with greater cumulative VL burden (log(10) viremia copy-years) during the first 2 years in care (Beta coefficient = 0.11 per 10% visit nonadherence, 95% confidence interval = 0.04 to 0.17). Across increasing visit adherence categories, lower cumulative VL burden was observed (mean ± standard deviation log(10) copy × years/mL); 0%-79% adherence: 4.6 ± 0.8; 80%-99% adherence: 4.3 ± 0.7; and 100% adherence: 4.1 ± 0.7 log(10) copy × years/mL, respectively (P < 0.01). CONCLUSIONS: Higher rates of early retention in HIV care are associated with achieving VL suppression and lower cumulative VL burden. These findings are germane for a test and treat approach to HIV prevention.
BACKGROUND: After HIV diagnosis and linkage to care, achieving and sustaining viral load (VL) suppression has implications for patient outcomes and secondary HIV prevention. We evaluated factors associated with expeditious VL suppression and cumulative VL burden among patients establishing outpatient HIV care. METHODS:Patients initiating HIV medical care from January 2007 to October 2010 at the University of Alabama at Birmingham and University of Washington were included. Multivariable Cox proportional hazards and linear regression models were used to evaluate factors associated with time to VL suppression (<50 copies/mL) and cumulative VL burden, respectively. Viremia copy-years, a novel area under the longitudinal VL curve measure, was used to estimate 2-year cumulative VL burden from clinic enrollment. RESULTS: Among 676 patients, 63% achieved VL <50 copies per milliliter in a median 308 days. In multivariable analysis, patients with more time-updated "no show" visits experienced delayed VL suppression (hazard ratio = 0.84 per "no show" visit, 95% confidence interval = 0.76 to 0.92). In multivariable linear regression, visit nonadherence was independently associated with greater cumulative VL burden (log(10) viremia copy-years) during the first 2 years in care (Beta coefficient = 0.11 per 10% visit nonadherence, 95% confidence interval = 0.04 to 0.17). Across increasing visit adherence categories, lower cumulative VL burden was observed (mean ± standard deviation log(10) copy × years/mL); 0%-79% adherence: 4.6 ± 0.8; 80%-99% adherence: 4.3 ± 0.7; and 100% adherence: 4.1 ± 0.7 log(10) copy × years/mL, respectively (P < 0.01). CONCLUSIONS: Higher rates of early retention in HIV care are associated with achieving VL suppression and lower cumulative VL burden. These findings are germane for a test and treat approach to HIV prevention.
Authors: T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray Journal: N Engl J Med Date: 2000-03-30 Impact factor: 91.245
Authors: Michael J Mugavero; Sonia Napravnik; Stephen R Cole; Joseph J Eron; Bryan Lau; Heidi M Crane; Mari M Kitahata; James H Willig; Richard D Moore; Steven G Deeks; Michael S Saag Journal: Clin Infect Dis Date: 2011-09-02 Impact factor: 9.079
Authors: Thomas P Giordano; A Clinton White; Prasuna Sajja; Edward A Graviss; Roberto C Arduino; Ahmed Adu-Oppong; Christopher J Lahart; Fehmida Visnegarwala Journal: J Acquir Immune Defic Syndr Date: 2003-04-01 Impact factor: 3.731
Authors: Michael J Mugavero; Hui-Yi Lin; James H Willig; Andrew O Westfall; Kimberly B Ulett; Justin S Routman; Sarah Abroms; James L Raper; Michael S Saag; Jeroan J Allison Journal: Clin Infect Dis Date: 2009-01-15 Impact factor: 9.079
Authors: Lytt I Gardner; Lisa R Metsch; Pamela Anderson-Mahoney; Anita M Loughlin; Carlos del Rio; Steffanie Strathdee; Stephanie L Sansom; Harvey A Siegal; Alan E Greenberg; Scott D Holmberg Journal: AIDS Date: 2005-03-04 Impact factor: 4.177
Authors: Jason A Craw; Lytt I Gardner; Gary Marks; Richard C Rapp; Jeff Bosshart; Wayne A Duffus; Amber Rossman; Susan L Coughlin; DeAnn Gruber; Lauretta A Safford; Jon Overton; Karla Schmitt Journal: J Acquir Immune Defic Syndr Date: 2008-04-15 Impact factor: 3.731
Authors: Lisa R Metsch; Margaret Pereyra; Shari Messinger; Carlos Del Rio; Steffanie A Strathdee; Pamela Anderson-Mahoney; Ellen Rudy; Gary Marks; Lytt Gardner Journal: Clin Infect Dis Date: 2008-08-15 Impact factor: 9.079
Authors: Mari M Kitahata; Benigno Rodriguez; Richard Haubrich; Stephen Boswell; W Christopher Mathews; Michael M Lederman; William B Lober; Stephen E Van Rompaey; Heidi M Crane; Richard D Moore; Michael Bertram; James O Kahn; Michael S Saag Journal: Int J Epidemiol Date: 2008-02-08 Impact factor: 7.196
Authors: Jeffrey H Herbst; Marlene Glassman; James W Carey; Thomas M Painter; Deborah J Gelaude; Amy M Fasula; Jerris L Raiford; Arin E Freeman; Camilla Harshbarger; Abigail H Viall; David W Purcell Journal: J Acquir Immune Defic Syndr Date: 2012-04-15 Impact factor: 3.731
Authors: Anne Zinski; Andrew O Westfall; Lytt I Gardner; Thomas P Giordano; Tracey E Wilson; Mari-Lynn Drainoni; Jeanne C Keruly; Allan E Rodriguez; Faye Malitz; D Scott Batey; Michael J Mugavero Journal: Am J Public Health Date: 2015-08-13 Impact factor: 9.308
Authors: Jessie K Edwards; Stephen R Cole; Jeffrey N Martin; Richard Moore; W Christopher Mathews; Mari Kitahata; Joseph J Eron; Michael Saag; Michael J Mugavero Journal: Clin Infect Dis Date: 2015-04-01 Impact factor: 9.079
Authors: Seonaid Nolan; Alexander Y Walley; Timothy C Heeren; Gregory J Patts; Alicia S Ventura; Meg M Sullivan; Jeffrey H Samet; Richard Saitz Journal: AIDS Care Date: 2017-05-17
Authors: David B Hanna; Nancy A Hessol; Elizabeth T Golub; Jennifer M Cocohoba; Mardge H Cohen; Alexandra M Levine; Tracey E Wilson; Mary Young; Kathryn Anastos; Robert C Kaplan Journal: J Acquir Immune Defic Syndr Date: 2014-04-15 Impact factor: 3.731
Authors: Angela Knudson; Sarah Shaw; Lu Yin; Dong Xiao; Han-Zhu Qian; Stephen Sullivan; Hongjie Liu; Yuhua Ruan; Yiming Shao; Sten H Vermund; K Rivet Amico Journal: AIDS Behav Date: 2019-05
Authors: Stephen T Wright; Jennifer Hoy; Brian Mulhall; Catherine C Oʼconnor; Kathy Petoumenos; Timothy Read; Don Smith; Ian Woolley; Mark A Boyd Journal: J Acquir Immune Defic Syndr Date: 2014-05-01 Impact factor: 3.731